Survival outcomes of primary vs interval cytoreductive surgery for International Federation of Gynecology and Obstetrics stage IV ovarian cancer: a nationwide population-based target trial emulation
This study advocates for the benefits of primary cytoreductive surgery over interval cytoreductive surgery for patients with stage IV ovarian cancer and suggests that extraperitoneal metastases like supradiaphragmatic or extra-abdominal lymph nodes should not automatically preclude primary cytoreductive surgery consideration in suitable patients.
Authors
- Anne‐Sophie Hamy (ORCID: https://orcid.org/0000-0003-4430-3022)
- Fabien Reyal (ORCID: https://orcid.org/0000-0002-2318-3589)
- Floriane Jochum (ORCID: https://orcid.org/0000-0001-5009-3936)
- Paul Gougis (ORCID: https://orcid.org/0000-0003-3064-7043)
- Élise Dumas (ORCID: https://orcid.org/0000-0002-7877-719X)
- Enora Laas (ORCID: https://orcid.org/0000-0003-3875-4011)
- Thomas Gaillard (ORCID: https://orcid.org/0000-0002-7062-9379)
- Denis Querleu (ORCID: https://orcid.org/0000-0002-3984-4812)
- Lise Lecointre
- Fabrice Lécuru (ORCID: https://orcid.org/0000-0002-4071-3932)
- Chérif Akladios (ORCID: https://orcid.org/0000-0001-6189-2741)
Institutions
- Inserm (FR)
- Agostino Gemelli University Polyclinic (IT)
- Sorbonne Université (FR)
- Immunité et Cancer (FR)
- Pitié-Salpêtrière Hospital (FR)
- Hôpital Civil, Strasbourg (FR)
- Université de Strasbourg (FR)
- Institut Curie (FR)
Publication Details
- Journal
- American Journal of Obstetrics and Gynecology
- Published
- 2024-08-05
- DOI
- https://doi.org/10.1016/j.ajog.2024.07.044
- Citations
- 15
- Primary Topic
- Ovarian cancer diagnosis and treatment
- Type
- article
- Field-Weighted Citation Impact
- 8.06